Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1996-09-06
1999-07-13
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
514479, 514480, 514481, 514484, 514423, A61K 3127, A61K 3140
Patent
active
059227613
ABSTRACT:
In accordance with the present invention, there are provided methods for the in vivo reduction of free iron ion levels in a mammalian subject. The present invention employs a scavenging approach whereby free iron ions are bound in vivo to a suitable physiologically compatible scavenger. The resulting complex renders the free iron ions harmless, and is eventually excreted in the urine of the host. Further in accordance with the present invention, there are provided compositions and formulations useful for carrying out the above-described methods. An exemplary scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-containing composition. This material binds to free iron ions, forming a stable, water-soluble dithiocarbamate-iron complex. The present invention relates to methods for reducing in vivo levels of free iron ions as a means of treating subjects afflicted with iron overload and non-iron overload diseases and/or conditions, such as thalassemia, anemia hereditary hemochromatosis, hemodialysis, stroke and rheumatoid arthritis. Dithiocarbamate-containing scavengers are administered to a host in need of such treatment; these scavengers interact with in vivo forming a stable dithiocarbamate-metal complex, which is then filtered through the kidneys, concentrated in the urine, and eventually excreted by the subject, thereby reducing in vivo levels of free iron ions.
REFERENCES:
patent: 4056621 (1977-11-01), Brown et al.
patent: 4160452 (1979-07-01), Theeuwes
patent: 4173644 (1979-11-01), Brown et al.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4894393 (1990-01-01), Nguyen et al.
patent: 5380747 (1995-01-01), Medford et al.
patent: 5430058 (1995-07-01), Shanzer et al.
Al-Refaie et al., "Efficacy and Possible Adverse Effects of the Oral Iron Chelator 1,2-Dimethyl-3-Hydroxypyrid-4-One (L.sub.1) in Thalassemia Major" Blood 80(3):593-599 (1992).
Biemond et al., "Intraarticular Ferritin-Bound Iron in Rheumatoid Arthritis" Arthritis Rheum. 29(10):1187-1193 (1986).
Biemond et al., "Iron Mobilization from Ferritin by Superoxide Derived from Stimulated Polymorphonuclear Leukocytes" J. Clin. Invest. 73:1576-1579 (1984).
De Sousa et al., "Iron, Iron-binding Proteins and Immune System Cells.sup.a " Ann. N.Y. Acad. Sci. 526:310-323 (1988).
De Virgiliis et al., "Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia" Arch. Dis. Chil. 63:250-255 (1988).
Dizdaroglu and Bergtold, "Charaterization of Free Radical-Induced Base Damage in DNA at Biologically Relevent Levels" Anal. Biochem. 156:182-188 (1986).
Guyader et al., "Evaluation of Computed Tomography in the Assessment of Liver Iron Overload" Gastroenterol. 97:737-743 (1989).
Haber and Weiss, "The Catalytic Decomposition of Hydrogen Peroxide by Iron Salts" Proc. R. Soc. Ser. A. 147:332-351 (1934).
Halliwell and Gutteridge, in Halliwell and Gutteridge, Free Radicals in Biology and Medicine, 2nd edition. Oxford: Clarendon Press, 15-19 (1989).
Harrison and Hoare, in Metals in Biochemistry, Chapman and Hall, New York, (1980).
Kim et al., "Loss and Degradation of Enzyme-bound Heme Induced by Cellular Nitric Oxide Synthesis" J. Biol. Chem. 270(11) :5710-5713 (1995).
Kolaric et al., "A Phase II Trial of Cardioprotection with Cardioxane (ICRF-187) in Patients with Advanced Breast Cancer Receiving 5-Fluorouracel, Doxorubicin and Cyclophosphamide" Oncology 52:251-255 (1995).
Komarov and Lai, "Detection of nitric oxide production in mice by spin-trapping electron paramagnetic resonance spectroscopy" Biochim. Biophys. Acta 1271:29-36 (1995).
Kontoghiorghes, G. J., "Advances in oral iron chelation in man" Int. J. Hematol. 55:27-38 (1992).
Kontoghiorghes, G. J., "Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs" Toxicol. Letters 80:1-18 (1995).
Lai and Komarov, "Spin trapping of nitric oxide produced in vivo in septic-shock mice" FEBS Letters 345:120-124 (1994).
Lai and Piette, "Hydroxyl Radical Production Involved in Lipid Peroxidation of Rat Liver Microsomes" Biochem. Biophys. Res. Commun. 78(1) :51-59 (1977).
Muirden and Senator, "Iron in the Synovial Membrane in Rheumatoid Arthritis and Other Joint Diseases" Ann. Rheum. Dis. 27:38-48 (1968).
Myers et al., "Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response" Science 197:165-167 (1977).
Pippard et al., "Ferrioxamine Excretion in Iron-Loaded Man" Blood 60(2) :288-294 (1982).
Proper et al., "Reassessment of the Use of Desferrioxamine B in Iron Overload" N. Engl. J. Med. 294(26) :1421-1423 (1976).
Rowley et al., "Lipid peroxidation in rheumatoid arthritis: thiobarbituric acid-reactive material and catalytic iron salts in snyovial fluid from rheumatoid patients" Clin. Sci. 66:691-695 (1984).
Shinobu et al., "Sodium N-Methyl-D-glucamine Dithiocarbamate and Cadmium Intoxication" Acta Pharmacol et Toxicol. 54:189-194 (1984).
Singal et al., "Subcellular Effects of Adriamycin in the Heart: A Concise Review" J. Mol. Cell. Cardiol. 19:817-828 (1987).
St. Louis et al., "Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients" Lancet 336:1275-1279 (1990).
Thomas et al., "The Hydrolysis Product of ICRF-187 Promotes Iron-Catalysed Hydroxyl Radical Production via the Fenton Reaction" Biochem. Pharmacol. 45(10) :1967-72 (1993).
Voest et al., "Iron-Chelating Agents in Non-Iron Overload Conditions" Ann. Intern. Med. 120(6) :490-499 (1994).
Vreugdenhil et al., "Efficacy and Safety of Oral Iron Chelator L.sub.1 in Anaemic Rheumatoid Arthritis Patients" Lancet 8:1398-1399 (1989).
Criares Theodore J.
Medinox Inc.
Reiter Stephen E.
LandOfFree
Methods for in vivo reduction of iron levels and compositions us does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for in vivo reduction of iron levels and compositions us, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for in vivo reduction of iron levels and compositions us will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2276089